

Unlocking the power of the immune system to fight cancer and autoimmune disease

Corporate Presentation - February 2025 (ASX: IMM; NASDAQ: IMMP)



The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.


The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This presentation is authorised for release by the CEO of Immutep Limited.










Information current as of February 2025. For EOC's China rights, Immutep may receive undisclosed milestones plus royalties. For Novartis' global rights to LAG525 (ieramilimab), Immutep may receive milestones plus royalties. # To date Novartis has conducted five separate clinical trials with LAG525. § Investigator-initiated trials controlled by lead investigator and Immutep has no control over these clinical trials. a In combination with KEYTRUDA[®]. In combination with BAVENCIO[®]. ## Conducted by EOC in China. * Three trials for IMP731 were conducted by GSK (two Phase I studies in healthy volunteers and psoriasis and a Phase II study in ulcerative colitis), which transitioned this clinical-stage asset back to Immutep in 2024.




Eftilagimod alfa (efti)

A first-in-class soluble LAG-3 fusion protein with high affinity for a subset of MHC Class II molecules on antigen-presenting cells (APCs)



Soluble Human lgG1 LAG-3 backbone



Efti activates powerful immune cells called dendritic cells by binding to MHC Class II. This activates a broad, sustained adaptive/innate immune response to fight cancer.* Cancer

Systemic Immune Effect Leading to Positive Clinical Outcomes



Encouraging data from efti in combination with IO, chemotherapy, radiotherapy across multiple indications LAG-3 IMMUN

Efti's subcutaneous delivery:

- Generates systemic anti-cancer immune response
- Improves patient experience vs. intravenous (IV) administration
 - ✓ Less invasive
 - ✓ Easier to administer
 - ✓ More flexible
- Potentially increases patient access to treatments

Non-Small Cell Lung Cancer

Head & Neck Squamous Cell Carcinoma

Melanoma

Advanced Solid Tumors (e.g., gastric, cervical)

Breast Cancer

Soft Tissue Sarcoma (first trial in neoadjuvant setting)

Efti + Anti-PD-1 Therapy

Efti + Anti-PD-L1 Therapy

Efti + Chemotherapy


Efti + Anti-PD-1 + Radiotherapy



Efti and Anti-PD-1 Therapy: A Unique, Complementary Combination




PD-1 inhibitors have reshaped cancer treatment yet alone they're effective in just ~20% of patients and their efficacy often depends on patients' PD-L1 expression levels.



Approved PD-(L)1 inhibitors in First Line Metastatic Non-Small Cell Lung Cancer

Efti's Differentiated, Complementary Approach with KEYTRUDA®





COMPLEMENTARY IMMUNITY

Efti's direct activation of dendritic cells initiates a complementary immune response with KEYTRUDA (anti-PD-1) to fight cancer

EXPANDS/ENHANCES RESPONSES

Efti + KEYTRUDA drives high-quality responses regardless of PD-L1 levels including in patients who typically don't respond well to anti-PD-1

FAVORABLE SAFETY PROFILE


Efti + KEYTRUDA has similar toxicity profile to KEYTRUDA alone yielding sought-after alignment of stronger efficacy & favourable safety

Significant Immune Activity with Efti + KEYTRUDA


Biomarker analyses of blood from multiple trials shows efti's positive impact on immune system



Significant increase in absolute lymphocyte count (ALC) linked to improved responses & shows efti's biological activity in randomised setting¹



Significant increases in Th1 biomarkers (IFN-γ & CXCL10) and absolute lymphocyte count driven by efti led to improved clinical outcomes²






~\$34 Billion of the pharma patent cliff in 2028 stems from PD-1 inhibitors¹

Immutep's comprehensive patent portfolio for efti provides an opportunity to enhance and substantially extend established or new PD-(L)1 franchises

Patent Expirations for Top 15 Drugs by Sales in 2023

Expiration dates of key patents related to US market





Efti in First Line Non-Small Cell Lung Cancer: The Key Value Driver

NSCLC Overview

- Lung cancer is leading cause of cancer death and 80-85% of lung cancers are non-small cell lung cancer (NSCLC)^{1,2}
- ~2.0 million NSCLC diagnoses annually
- Despite advances, Overall Survival still under 2 years for most patients
- Total addressable NSCLC drug market expected to reach US\$48 billion in 2031 with >50% sales from ICIs (e.g. anti-PD-1)³

1. Calculated from Global Cancer Observatory (WHO), 2022 data & American Cancer Society, About Lung Cancer; 2.Tang S et al. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells. 2022 Jan 19;11(3):320. doi: 10.3390/cells11030320; 3. Nature Reviews Drug Discovery 22, 264-265 (23 Jan 2023) doi: https://doi.org/10.1038/d41573-023-00017-9.

TACTI-002 / KN-798 Trial Overview and Baseline Characteristics

Part A: Large Phase II trial in advanced/metastatic first line non-small cell lung cancer (1L NSCLC)



TACTI-002 (Part A) Phase II: Overview & Trial Design

Overview	Screening incl. PD-L1 testing	Screening incl. PD-L1 testing Treatment Pha			Follow Up Phase
 Status: Completed Enrolment: 114 patients Locations: 18 centers across six countries: US, UK, ES, PL, UA, and AU 	 Advanced/metastatic 1L NSCLC 0-100% PD-L1 expression EGFR/ALK negative 	Combination Therapy 30mg efti Q2W + 200 mg pembrolizumab Q3W for 8 cycles, followed by 30mg efti + 200mg pembrolizumab for 9 cycles	Monotherapy 200 mg pembrolizumab Q3W for 16 cycles	•	Primary endpoint: ORR by iRECIST Secondary Endpoints: ORR by RECIST 1.1, PFS, OS, DOR, safety, PK/PD
In collaboration with		Up to 1 year	Up to 1 year		
MSD	Baseline patient characterist	tics	N=114		
	Age, median (range), years		67 (44-85)		
	Sex, n (%)	Female / Male	30 (26.3) / 84 (73.7)		
	ECOG PS score, n (%)	0/1	43 (37.7) / 71 (62.3)		
	Smoking status, n (%)	Current or Ex-smoker / Non-smoker	108 (94.7) / 6 (5.3)		
	Histology, n (%)	Squamous / Non-squamous / Unknown	40 (35.1) / 72 (63.2) / 2 (1.8)		
	Metastatic disease, n (%)	Yes / No	113 (99.1) / 1 (0.9)		TACTI-002 enrolled 1L NSCLC
	PD-L1 expression TPS, n (%)	< 1% 1-49% ≥ 50%	Central only 1 Central + local 2 32 (35.6) 37 (34.3) 38 (42.2) 42 (38.9) 20 (22.2) 29 (26.9)		 patients regardless of PD-L1 expression and ~25% had hig PD-L1 (TPS ≥50%), a lower proportion than typically
	Previous therapy, n (%)	Radiotherapy Surgery Systemic therapy for non-metastatic disease	38 (33.3) 23 (20.2) 26 (22.8)		would be expected.



Tumor Response by PD-L1 Expression Level¹

	All-Comer	Negative PD-L1	Low PD-L1	Any PD-L1	High PD-L1
	TPS 0-100% _{N=114}	TPS <1% _{N=32}	TPS 1-49% _{N=38}	TPS ≥1% _{N=58}	TPS ≥50% _{N=20}
ORR ^{2,3,4}	40.4%	31.3%	44.7%	48.3%	55.0%
mPFS ² , months	6.6	4.2	9.3	11.2	16.5
mDoR ² , months	21.6	20.7	NR	24.2	18.7
mOS, months	20.2	15.5	23.4	35.5	Not Reached

ORR – Overall Response Rate

mPFS – median Progression Free Survival


mDOR – median Duration of Response

mOS – median Overall Survival

- Results offer compelling evidence of efti's unique stimulation of patients' immune systems and its potential to fight cancer
- Strong efficacy across all PD-L1 levels differentiates efti + anti-PD-1 (KEYTRUDA) from other chemotherapy-free combinations in 1L NSCLC
- Excellent Overall Survival, the gold standard benchmark in oncology, with exceptional durability, quality of responses, and favorable safety profile

immutep

Robust response rates, durability, and progression free survival from efti plus pembrolizumab across all PD-L1 expression levels translate into compelling overall survival



Efti + Pembrolizumab

Pembrolizumab monotherapy

Comparison of data is from different clinical trials. Pembrolizumab monotherapy data from publications/EPAR asessment report of KN-042 registrational trial. Given the lack of historical results in negative PD-L1 expressing 1L NSCLC patients who received pembrolizumab monotherapy in KN-042 and other trials, the chart only has data from patients in TACTI-002 with negative PD-L1 expression (TPS <1%). In 1L NSCLC patients with TPS \geq 1%, TACTI-002 has 66% patients with TPS 1-49% and 34% with TPS \geq 50%, which compares to KN-042 with ~53% patients with PD-L1 and ~47% patients with PD-L1 TPS \geq 50%.



Differentiated OS from Efti + Pembrolizumab achieved with a favorable safety profile

Therapy in 1L NSCLC TPS <u>></u> 1%	Drug-related Adverse Events Leading to Discontinuation ²	Median Overall Survival ³			
Efti + Pembrolizumab	→ 9.6%	35.5 months			
Pembro + Doublet Chemo (NSQ)	20.5%	23.3 months			
Pembro + Doublet Chemo (SQ)	16.8%	18.9 months			
Ipilimumab + Nivolumab ¹	18.1%	17.1 months			
Pembrolizumab monotherapy ¹	9.9%	16.4 months			
Ipi + Nivo + 2 cycles of Doublet Chemo	22.1%	15.8 months			

NSQ = Non-squamous; SQ = Squamous

Comparison of data is from different clinical trials. 1. Ipilimumab + Nivolumab approved in US for 1L NSCLC PD-L1 TPS >1% but not in EU; Pembro mono not approved in Europe for TPS 1-49%. 2. Treatment related adverse events leading to discontinuation taken from publications/EPAR assessments of respective trials (KN-042, KN-024, KN-189, KN-021, KN-407, CM-227, CM-9LA). 3. Arrow lengths are proportional representations of Overall Survival data. Data for standard-of-care therapies taken from publications of respective registrational trials (e.g., KN-042, KN-189, KN-407, CM-227, CM-9LA).

INSIGHT-003: Excellent Mature Survival Data

Promising efficacy & safety from first-in-human study evaluating Efti + KEYTRUDA + doublet chemo



INSIGHT-003 (Stratum C) Phase I: Overview & Trial Design



Efti + Pembrolizumab + chemo¹


Pembrolizumab + chemo²

Comparison of data is from different clinical trials. 1. Data cut-off date is 15 October 2024 for INSIGHT-003. * Objective Response Rate (N=40) and Overall Survival & Progression Free Survival data from patients with mature follow up of at least 22 months (N=21). Of note, INSIGHT-003 has ~19% patients with high PD-L1 who typically respond better to anti-PD-1 vs ~32% patients in historical control. 2. Shirish Gadgeel et al., Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer. JCO 38, 1505-1517(2020). DOI:10.1200/JCO.19.03136. * After 24 weeks, efti is injected every 3 weeks when combined with the SOC therapy or every 2 weeks as monotherapy.

Immutep & MSD (Merck) Phase III Trial in 1L NSCLC



TACTI-004 / KEYNOTE-PNC-91 Phase III: Overview & Trial Design



Upcoming Milestones	1 st Patient In		< Futility	< Futility Analysis>				< Interim Analysis>		
	Q1′25	Q2'25	Q3'25	YE'25	Q1'26	Q2'26	Q3'26	YE'26	Q1′27	

Global Phase III 1L NSCLC Trials with KEYTRUDA in Treatment Arm




TACTI-004 addresses the broadest 1L NSCLC patient population eligible for anti-PD-1 therapy

	PD-L1 TPS <1	PD-L1 TPS 1-49	PD-L1 TPS <u>></u> 50	Non-squamous	Squamous	Total Population
1L NSCLC patient population*	35%	35%	30%	70%	30%	Up to 100%
TACTI-004 (Immutep) Efti + KEYTRUDA + Chemo	✓	✓	✓	✓	✓	100%
TROPION-Lung07 (Daiichi Sankyo) DatoDXd + KEYTRUDA	~	~	×	~	×	49%
EVOKE-03 (Gilead) Sacituzumab Govitecan + KEYTRUDA	×	×	~	×	×	30%
TROPION-Lung08 (Daiichi Sankyo) DatoDXd + KEYTRUDA	×	×	~	~	×	21%



If TACTI-004 is successful it presents a potential multi-billion US\$ opportunity for Immutep as efti will be positioned as a safe, effective addition to KEYTRUDA & chemo, the standard-of-care therapy most often chosen by physicians in 1L NSCLC:

- KEYTRUDA has revolutionized treatment landscape and MSD (Merck) captures between 7 to 8 of every 10 patients with metastatic lung cancer^{*}
- Estimates are ~US\$9 billion or +35% of KEYTRUDA's overall sales in 2023 from lung cancer^{**}
- Potential peak sales for efti can be reached faster vs. typical therapeutic launch given KEYTRUDA + chemo's dominant position in 1L NSCLC market






Additional Oncology Indications & Small Molecule Anti-LAG-3 Oncology Program

TACTI-003 / KN-C34 Trial Overview

Efti + anti-PD-1 therapy has FDA Fast Track designation in recurrent or metastatic 1L HNSCC




TACTI-003 / KEYNOTE-C34 Phase IIb: Overview & Trial Design



In collaboration with




- Randomised, multicenter Phase IIb trial evaluating efti in combination with pembrolizumab (KEYTRUDA[®]) in first line recurrent or metastatic head and neck squamous cell carcinoma (1L R/M HNSCC):
 - Cohort A (N=138) Patients with any PD-L1 expression (CPS ≥1) randomised 1:1 evaluating efti + KEYTRUDA[®] vs. KEYTRUDA monotherapy
 - Cohort B (N=33) Patients with no PD-L1 expression (CPS <1), which could not be randomised as KEYTRUDA monotherapy not approved in CPS <1
- Primary endpoint is Objective Response Rate (ORR) among evaluable patients (> 1 post baseline CT), according to RECIST1.1
- Secondary endpoints include Overall Survival and Progression-Free Survival, ORR (iRECIST), and Disease Control Rate



Objective Response Rate (ORR)

Disease Control Rate (DCR)



Efti + KEYTRUDA (TACTI-003) KEYTRUDA mono (TACTI-003)

KEYTRUDA mono (KN-048)*

Data cut-off date: 11 March 2024 (additional response after data cut-off was reported in CPS ≥20 leading to 34.5% ORR). * Source: Burtness, B. et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-24 048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J. Clin. Oncol. 2022 40:21, 2321-2332



Safety Parameter	KEYTRUDA alone (Cohort A, n=68) n (%)	Efti + KEYTRUDA (Cohort A, n=69) n (%)	Efti + KEYTRUDA (Cohort B, n=33) n (%)
Any TEAR Leading to Discontinuation of Study Treatment	3 (4.4%) ¹	3 (4.3%) ²	3 (9.1%) ³
TEAR: Treatment-emergent adverse reaction			


• No new safety signals

- Rate of treatment related discontinuation was low and comparable between treatment regimens
- Safety profile comparable to KEYTRUDA monotherapy


Cohort B: Exceptional Results for a Chemo-Free Regimen


Benchmarking to KEYTRUDA monotherapy in patients with PD-L1 expression below 1 (CPS <1)











>890,000 HNSCC diagnoses per annum worldwide with ~100,000 patients who develop metastatic disease.^{1,2,3}

Efti + KEYTRUDA shows superior OS, PFS, and durability with less toxicity as compared to SOC therapies & generates high response rates.

Next Steps

- Discuss the path forward in 1L HNSCC CPS <1 with regulatory agencies
- Discuss results with key stakeholders (investigators etc.)

1. Extracted from GlobalData in June 2024, 8 Major Markets: US, China, Japan, France, Germany, Italy, Spain, UK. 2. Gormley, M., Creaney, G., Schache, A. et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. *Br Dent J* (2022). https://doi.org/10.1038/s41415-022-5166-x. 3. Johnson, D.E., Burtness, B., Leemans, C.R. et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6, 92 (2020), https://doi.org/10.1038/s41572-020-00224-3. 4. Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study The Lancet Volume 394, Issue 10212, P1915-1928, Nov 2019.


Positive Data in Soft Tissue Sarcoma Presented at CTOS 2024

Phase II studying novel triple combination of Efti + Radiotherapy + KEYTRUDA in soft tissue sarcoma (STS)


Instante and the second second

Narodowy

EFTISARC-NEO Phase II: Overview & Trial Design



Strong efficacy in patients assessed for tumour hyalinization/fibrosis, trial's primary endpoint associated with improved survival in STS patients¹




RESEARCH ARTICLE

Cancer Medicine WILEY


Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma

Sneha R. Rao¹ ◎ | Alexander L. Lazarides¹ ◎ | Bruce L. Leckey² | Whitney O. Lane³ | Julia D. Visgauss¹ | Jason A. Somarelli⁴ | David G. Kirsch⁵ ◎ | Nicole A. Larrier⁵ | Brian E. Brigman¹ | Dan G. Blazer³ | Diana M. Cardona² | William C. Eward¹

50% tumour hyalinization/fibrosis vs. 15% from RT alone²




71.4% patients achieved pathologic response (hyalinization >35%) across five STS subtypes





AIPAC-003: Overview and Trial Design






- HR+/- HER2-negative/low and triple negative metastatic breast cancer (MBC) patients represent ~78% breast cancer cases¹
- Patients receive efti + paclitaxel on same day; IO-chemo treatment can continue until disease progression
- Trial design incorporates feedback from FDA & EMA and provides risk-balanced approach
- Randomised Phase II dose optimization underway to find optimal biological efti dosing (e.g. 30mg or 90mg)



INSIGHT-005 (Stratum E) Phase I: Overview & Trial Design



INSIGHT-005 is an investigator-initiated, multi-centre Phase I trial led by Frankfurt Institute of Clinical Cancer Research (IKF)

In collaboration with



- INSIGHT-005 evaluating safety & efficacy of efti and avelumab (BAVENCIO[®]), which has previously shown promising efficacy in solid tumours in Phase I trial
- Jointly funded by Immutep & Merck KGaA, Darmstadt, Germany
- Targeting area of high unmet need: patients not eligible for platinum-based chemotherapy or who are progressing during/after platinum-based chemotherapy
- Announced first patient enrolled and safely dosed in Jan 2024






Immutep aims to develop an orally-available small molecule anti-LAG-3 treatment at a lower cost compared with anti-LAG-3 antibodies commercially available (Opdualag; ~\$864 million in TTM sales^{**}) or under clinical development

"Small molecules represent the next generation of anti-LAG-3 therapies and hold tremendous promise, as they can be given to cancer patients as a convenient oral pill."

> Professor Andrew Godkin, Theme Lead in Immunology in the College of Biomedical Life Sciences, Cardiff University

31

Anti-LAG-3 Antibody Clinical Trials^{*}





IMP761: First-in-class LAG-3 Agonist Antibody for Autoimmune Diseases

Targeting Autoimmune Diseases with a LAG-3 Checkpoint Agonist




New paradigm to treat the cause -- as opposed to the symptoms -- of autoimmune disorders



"These findings further support the potential clinical benefits of a **LAG-3 agonist** in the treatment of human autoimmunity"¹

Research & Therapy

"LAG-3 agonism could be a potential target for future treatment in rheumatoid arthritis"² Unique advantages of LAG-3 make it an ideal target for an agonist antibody to treat autoimmune diseases





"The manipulation of the LAG-3 pathway can serve as a promising therapeutic strategy"

1. Britta E. Jones, Megan D. Maerz, Henry T. Bahnson, Ashwin Somasundaram, Lucas H. McCarthy, Cate Speake, Jane H. Buckner; Fewer LAG-3+ T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes. J Immunol 1 February 2022; 208 (3): 594–602. https://doi.org/10.4049/jimmunol.2100850. 2. Pedersen, J.M., Hansen, A.S., Skejø, C. et al. Lymphocyte activation gene 3 is increased and affects cytokine production in rheumatoid arthritis. Arthritis Res Ther 25, 97 (2023). https://doi.org/10.1186/s13075-023-03073-z. 3. Zhou, X., Gu, Y., Wang, H. et al. From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases. Inflamm. Res. 72, 1215–1235 (2023). https://doi.org/10.1007/s00011-023-01742-y

LAG-3: An Important Immune Checkpoint in Autoimmunity

Learnings from immune checkpoint inhibitors (ICI) in oncology



ICI therapies (e.g. anti-PD-[L]1, anti-CTLA-4, anti-LAG-3) are effective in many oncology indications

Main side effects of ICIs are emergence of autoimmune disorders (e.g. immune-mediated pneumonitis, colitis, hepatitis, thyroiditis, etc.) due to overactivation of the immune system

Immune checkpoints are controlling autoimmunity

Addition of relatlimab (anti-LAG-3) mostly *doubled frequency of immune mediated AEs* vs. nivolumab (anti-PD-1)¹

RELATIVITY-047 Phase III trial in Melanoma

Adverse Events (AE) %	Relatlimab + Nivolumab (N = 355)	Nivolumab alone (N = 359)
Hypothyroidism or thyroiditis	18.0	13.9
Arthralgia	14.4	7.2
Diarrhea or colitis	6.8	3.1
Hepatitis	5.6	2.5
Adrenal insufficiency	4.2	0.8
Pneumonitis	3.7	1.7
Hypophysitis	2.5	0.8
Myocarditis	1.7	0.6

LAG-3 is an important checkpoint in autoimmunity


1. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. PMID: 34986285; PMCID: PMC9844513.

IMP761: First-in-Class LAG-3 Agonist is a Potential Game-Changer



Many autoimmune diseases can potentially be targeted including several large disorders


IMP761 increases "brake" function of the LAG-3 immune checkpoint and its natural down-regulation of auto-reactive memory T cells, which represent the root cause of many diseases



IMP761 as a LAG-3 agonist can target numerous autoimmune diseases including:

- Rheumatoid arthritis: market size est. \$29.6 billion*
- Type 1 diabetes: market size est. \$9.9 billion*
- Multiple sclerosis: market size est. \$32.9 billion*





Unique LAG-3 Signalling Pathway

- Unlike 100+ inhibitory receptors (including PD-1, TIGIT, BTLA), LAG-3 has no tyrosine-based ITIM motif¹ in its cytoplasmic domain
- The inhibitory motifs unique to LAG-3² explain in part *clear & rapid inhibition of T cell receptor (TCR) signalling* induced by IMP761 in preclinical studies
- IMP761 also strongly blocks T cell activation via the TCR in preclinical studies

1. ITIM motif (S/I/V/LxYxxI/V/L). 2. Three unique inhibitory motifs (KIEELE, repeated EP, FXXL). Lui, Y., Davis, S.J. LAG-3: a very singular immune checkpoint. Nat Immunol 19, 1278–1279 (2018) https://doi.org/10.1038/s41590-018-0257-1. N Jantz-Naem et al, Front. Oncol., 17 February 2023, Sec. Cancer Metabolism, Vol 13 -https://doi.org/10.3389/fonc.2023.1060112. Maeda, Takeo K. et al. Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation Journal of Biological Chemistry, April 2019, Volume 294, Issue 15, 6017 - 6026

Clinical Development of IMP761



Leading world-class research institute appointed to conduct first-in-human study

Overview / Key Milestones:

- Placebo-controlled, double-blind Phase I (N = 49)
- Centre for Human Drug Research (CHDR) has been selected to conduct
- First participant enrolled in August 2024
- Favourable initial safety data reported in December 2024
- Additional data and study completion expected in 2025

Single Ascending Dose (SAD): Healthy volunteers




Multiple Ascending Dose (MAD): Healthy volunteers






- World-class research institute in Leiden, the Netherlands
- CHDR offers a unique KLH challenge model allowing for evaluation of IMP761's pharmacological activity at early stages of development



Outlook





2025 Milestones

- Non-Small Cell Lung Cancer:
 - FPI in TACTI-004 Phase III in Q1 CY2025
 - TACTI-004 potential futility analysis by year end CY2025 or early 2026^{*}
 - Update from investigator-initiated INSIGHT-003 trial
- Metastatic Breast Cancer Update from AIPAC-003 trial
- Head and Neck Squamous Cell Carcinoma Update from TACTI-003 trial
- Soft Tissue Sarcoma Update from investigator-initiated EFTISARC-NEO trial
- Metastatic Urothelial Carcinoma Update from investigator-initiated INSIGHT-005 trial
- Autoimmune Diseases Update from IMP761 first-in-human Phase I trial
- Additional Updates From ongoing clinical trials, partnered programs, and potential expansion of clinical trial pipeline





Thank You